

**Clean Copy of Amended Claims- Please Enter**

(A marked-up copy of the claims showing the changes is attached)

A1  
1. (Amended) A method for treating sexual arousal disorder comprising:  
administering to a female subject in need thereof, an effective amount of an  
estrogen agonist / antagonist, and optionally,  
co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate  
elevator.

A2  
11. (Amended) A method as in claim 10 wherein said cyclic guanosine 3',5'-  
monophosphate elevator is a PDE<sub>V</sub> phosphodiesterase inhibitor.

12. (Amended) A method as in claim 11 wherein the PDE<sub>V</sub> phosphodiesterase  
inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-  
yl)-4-ethoxy-phenyl]sulfonyl]-4-methylpiperazine citrate salt.

**Remarks**

Applicants hereby elect to prosecute the claims of Group I, claims 1-14, which  
relate to methods of treatment. Applicants have also been required to elect an "ultimate  
✓ formula." Applicants hereby elect formula I of claim 2. The claims that read on formula  
I are claims 1-5 and 10-12. In addition, Applicants have been required to elect a species.  
Applicants hereby elect the species of claim 4, which is (-)-cis-6-phenyl-5-[4-(2-  
✓ pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. Last, Applicants  
have been required to elect a disorder. Applicants hereby elect the disorder of sexual  
✓ arousal disorder.

Claims 6-9 and 13-36 have been cancelled without prejudice to filing divisional  
applications, as these claims relate to non-elected subject matter. Claims 1, 11 and 12  
have been amended to reflect the election of sexual arousal disorder as the disorder and to  
correct errors in dependencies.

Applicants believe that claims 1-5 and 10-12 are in condition for allowance.  
Consideration and allowance of claims 1-5 and 10-12 is respectfully requested.

Respectfully yours,

Date: 11/25/2002

By: Todd M. Crissey

Todd M. Crissey

Registration No. 37,807


Pfizer Inc

Eastern Point Road, MS 4159

Groton, CT 06340

Phone: (860) 715-4331

Fax: (860) 441-5221



COPY OF PAPERS  
ORIGINALLY FILED

Attorney Docket No. PC10636ATMC  
Application No. 09/833,169

RECEIVED

FEB 26 2002

TECH CENTER 1600/29

Attachment  
Marked Up Copy of Amended Claims

1. (Amended) A method for treating [female sexual dysfunction] sexual arousal disorder comprising:  
administering to a female subject in need thereof, an effective amount of an estrogen agonist / antagonist, and optionally,  
co-administering an effective amount of a cyclic guanosine 3',5'-monophosphate elevator.
11. (Amended) A method as in claim [8] 10 wherein said cyclic guanosine 3',5'-monophosphate elevator is a PDE<sub>v</sub> phosphodiesterase inhibitor.
12. (Amended) A method as in claim [5] 11 [further comprising co-administering] wherein the PDE<sub>v</sub> phosphodiesterase inhibitor is 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sulfonyl]-4-methylpiperazine citrate salt.